Meridian Bioscience (NASDAQ:VIVO) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 125.52%, resulting in a loss of $7.34 million.
Meridian Bioscience (NASDAQ:VIVO) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $0.16.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Meridian Bioscience, Inc. (NasdaqGS: VIVO) to SD Biosensor, Inc. and SJL Partners LLC. Under the terms of the proposed transaction, shareholders of Meridian will receive only $34.00 in cash for each share of Meridian that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Meridian Bioscience, Inc. (NASDAQ: VIVO) to SD Biosensor, Inc. and SJL Partners LLC for $34.00 per share in cash is fair to Meridian shareholders.
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
